Primum Non Nocere
Charting (and Publishing) the Boundaries of Critical Illness
Is Idiopathic Pulmonary Fibrosis Now Treatable?
One Hundred Years of Chronic Obstructive Pulmonary Disease
Promoter Analysis and Aberrant Expression of the MUC5B Gene in Diffuse Panbronchiolitis
ADAM33 Expression in Asthmatic Airways and Human Embryonic Lungs
The Association of Acetaminophen, Aspirin, and Ibuprofen with Respiratory Disease and Lung Function
Characteristics of Physical Activities in Daily Life in Chronic Obstructive Pulmonary Disease
Inhibition of c-Jun N-Terminal Kinase Limits Lipopolysaccharide-induced Pulmonary Neutrophil Influx
Risk of Post-traumatic Stress Symptoms in Family Members of Intensive Care Unit Patients
Pediatric Acute Lung Injury
Effects of High versus Low Positive End-Expiratory Pressures in Acute Respiratory Distress Syndrome
Closed-Loop Control of Respiratory Drive Using Pressure-Support Ventilation
Potential Difference Measurements in the Lower Airway of Children with and without Cystic Fibrosis
Effects of Segregation on an Epidemic Pseudomonas aeruginosa Strain in a Cystic Fibrosis Clinic
Chloride Transport in Nasal Ciliated Cells of Cystic Fibrosis Heterozygotes
Vitamin C Prevents the Effects of Prenatal Nicotine on Pulmonary Function in Newborn Monkeys
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Cheyne-Stokes Respiration in Stroke
Use of Lung Transplantation Survival Models to Refine Patient Selection in Cystic Fibrosis
An Own GOAL or a Real Breakthrough?
The GOAL Study Designed to Favor a Long-acting β2-Agonist?
The GOAL Study Designed to Favor a Long-acting β2-Agonist?